Filing Details

Accession Number:
0001140361-16-047651
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-01-12 17:38:45
Reporting Period:
2016-01-11
Filing Date:
2016-01-12
Accepted Time:
2016-01-12 17:38:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1302573 Oncomed Pharmaceuticals Inc OMED Pharmaceutical Preparations (2834) 383572512
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1553335 Jakob Dupont C/O Oncomed Pharmaceuticals, Inc.
800 Chesapeake Drive
Redwood City CA 94063
Svp & Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-01-11 2,500 $4.56 23,142 No 4 M Direct
Common Stock Disposition 2016-01-11 2,500 $20.01 20,642 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2016-01-11 2,500 $0.00 2,500 $4.56
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
138,937 2021-10-24 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 5, 2015.
  2. Includes 15,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
  3. This transaction was executed in multiple trades in prices ranging from $20.00 to $20.08, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. The option was immediately exercisable in full on October 24, 2011; however, the shares vest pursuant to the following schedule: Twenty Percent (20%) of the shares subject to the option vest on the first anniversary measured from October 1, 2011 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 48 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.